Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 69

1.

Regulation of gap junction intercellular communication by connexin ubiquitination: physiological and pathophysiological implications.

Totland MZ, Rasmussen NL, Knudsen LM, Leithe E.

Cell Mol Life Sci. 2019 Sep 9. doi: 10.1007/s00018-019-03285-0. [Epub ahead of print] Review.

PMID:
31501970
2.

[Cancer immune therapy for the treatment of haematological malignancies].

Holmström MO, Klausen U, Jørgensen NG, Holmberg S, Grauslund J, Met Ö, Svane IM, Pedersen LM, Knudsen LM, Hasselbalch HC, Andersen MH.

Ugeskr Laeger. 2019 Mar 4;181(10). pii: V06180421. Danish.

PMID:
30869069
3.

Treatment strategies and outcomes in diffuse large B-cell lymphoma among 1011 patients aged 75 years or older: A Danish population-based cohort study.

Juul MB, Jensen PH, Engberg H, Wehberg S, Dessau-Arp A, Haziri D, Kristensen HB, Baech J, Schurmann L, Clausen MR, Valentin R, Knudsen LM, Munksgaard L, El-Galaly TC, Frederiksen H, Larsen TS.

Eur J Cancer. 2018 Aug;99:86-96. doi: 10.1016/j.ejca.2018.05.006. Epub 2018 Jun 20.

PMID:
29935491
4.

The E3 ubiquitin ligase NEDD4 induces endocytosis and lysosomal sorting of connexin 43 to promote loss of gap junctions.

Totland MZ, Bergsland CH, Fykerud TA, Knudsen LM, Rasmussen NL, Eide PW, Yohannes Z, Sørensen V, Brech A, Lothe RA, Leithe E.

J Cell Sci. 2017 Sep 1;130(17):2867-2882. doi: 10.1242/jcs.202408. Epub 2017 Jul 21.

5.

Peptide vaccination against multiple myeloma using peptides derived from anti-apoptotic proteins: a phase I trial.

Jørgensen NG, Ahmad SM, Abildgaard N, Straten PT, Svane IM, Andersen MH, Knudsen LM.

Stem Cell Investig. 2016 Dec 23;3:95. doi: 10.21037/sci.2016.11.09. eCollection 2016.

6.

Mitotic cells form actin-based bridges with adjacent cells to provide intercellular communication during rounding.

Fykerud TA, Knudsen LM, Totland MZ, Sørensen V, Dahal-Koirala S, Lothe RA, Brech A, Leithe E.

Cell Cycle. 2016 Nov;15(21):2943-2957. Epub 2016 Sep 13.

7.

FDG PET/CT in cancer: comparison of actual use with literature-based recommendations.

Petersen H, Holdgaard PC, Madsen PH, Knudsen LM, Gad D, Gravergaard AE, Rohde M, Godballe C, Engelmann BE, Bech K, Teilmann-Jørgensen D, Mogensen O, Karstoft J, Johansen J, Christensen JB, Johansen A, Høilund-Carlsen PF; PET/CT Task Force of the Region of Southern Denmark.

Eur J Nucl Med Mol Imaging. 2016 Apr;43(4):695-706. doi: 10.1007/s00259-015-3217-0. Epub 2015 Oct 30.

8.

Practical planning to maintain premature infants' safety during magnetic resonance imaging: a systematic review.

Knudsen LM, Moen A.

Adv Neonatal Care. 2015 Feb;15(1):23-37; quiz E1-2. doi: 10.1097/ANC.0000000000000142. Review.

PMID:
25626980
9.

Myeloma plasma cell expression of osteoblast regulatory genes: overexpression of SFRP3 correlates with clinical bone involvement at diagnosis.

Kristensen IB, Haaber J, Lyng MB, Knudsen LM, Rasmussen T, Ditzel HJ, Abildgaard N.

Leuk Lymphoma. 2013 Feb;54(2):425-7. doi: 10.3109/10428194.2012.708027. Epub 2012 Aug 7. No abstract available.

PMID:
22742577
10.

Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized study.

Hjorth M, Hjertner Ø, Knudsen LM, Gulbrandsen N, Holmberg E, Pedersen PT, Andersen NF, Andréasson B, Billström R, Carlson K, Carlsson MS, Flogegård M, Forsberg K, Gimsing P, Karlsson T, Linder O, Nahi H, Othzén A, Swedin A; Nordic Myeloma Study Group (NMSG).

Eur J Haematol. 2012 Jun;88(6):485-96. doi: 10.1111/j.1600-0609.2012.01775.x. Epub 2012 Mar 30.

11.

Increased level of both CD4+FOXP3+ regulatory T cells and CD14+HLA-DR⁻/low myeloid-derived suppressor cells and decreased level of dendritic cells in patients with multiple myeloma.

Brimnes MK, Vangsted AJ, Knudsen LM, Gimsing P, Gang AO, Johnsen HE, Svane IM.

Scand J Immunol. 2010 Dec;72(6):540-7. doi: 10.1111/j.1365-3083.2010.02463.x.

12.

Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial.

Gimsing P, Carlson K, Turesson I, Fayers P, Waage A, Vangsted A, Mylin A, Gluud C, Juliusson G, Gregersen H, Hjorth-Hansen H, Nesthus I, Dahl IM, Westin J, Nielsen JL, Knudsen LM, Ahlberg L, Hjorth M, Abildgaard N, Andersen NF, Linder O, Wisløff F.

Lancet Oncol. 2010 Oct;11(10):973-82. doi: 10.1016/S1470-2045(10)70198-4.

PMID:
20863761
13.

Multiparametric flow cytometry profiling of neoplastic plasma cells in multiple myeloma.

Johnsen HE, Bøgsted M, Klausen TW, Gimsing P, Schmitz A, Kjaersgaard E, Damgaard T, Voss P, Knudsen LM, Mylin AK, Nielsen JL, Björkstrand B, Gruber A, Lenhoff S, Remes K, Dahl IM, Fogd K, Dybkaer K; Nordic Myeloma Study (NMSG); Myeloma Stem Cell Network (MSCNET).

Cytometry B Clin Cytom. 2010 Sep;78(5):338-47. doi: 10.1002/cyto.b.20523. Epub 2010 Apr 28.

14.

Identification of translocation products but not K-RAS mutations in memory B cells from patients with multiple myeloma.

Rasmussen T, Haaber J, Dahl IM, Knudsen LM, Kerndrup GB, Lodahl M, Johnsen HE, Kuehl M.

Haematologica. 2010 Oct;95(10):1730-7. doi: 10.3324/haematol.2010.024778. Epub 2010 May 29.

15.

Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma.

Waage A, Gimsing P, Fayers P, Abildgaard N, Ahlberg L, Björkstrand B, Carlson K, Dahl IM, Forsberg K, Gulbrandsen N, Haukås E, Hjertner O, Hjorth M, Karlsson T, Knudsen LM, Nielsen JL, Linder O, Mellqvist UH, Nesthus I, Rolke J, Strandberg M, Sørbø JH, Wisløff F, Juliusson G, Turesson I; Nordic Myeloma Study Group.

Blood. 2010 Sep 2;116(9):1405-12. doi: 10.1182/blood-2009-08-237974. Epub 2010 May 6.

PMID:
20448107
16.

Regulation of the CD56 promoter and its association with proliferation, anti-apoptosis and clinical factors in multiple myeloma.

Damgaard T, Knudsen LM, Dahl IM, Gimsing P, Lodahl M, Rasmussen T.

Leuk Lymphoma. 2009 Feb;50(2):236-46. doi: 10.1080/10428190802699332.

PMID:
19235015
17.

Serum YKL-40 and bone marrow angiogenesis in multiple myeloma.

Mylin AK, Andersen NF, Johansen JS, Abildgaard N, Heickendorff L, Standal T, Gimsing P, Knudsen LM.

Int J Cancer. 2009 Mar 15;124(6):1492-4. doi: 10.1002/ijc.24110. No abstract available.

18.

Upregulated MCL1 mRNA expression in multiple myeloma lacks association with survival.

Mylin AK, Rasmussen T, Lodahl M, Dahl IM, Knudsen LM.

Br J Haematol. 2009 Mar;144(6):961-3. doi: 10.1111/j.1365-2141.2008.07521.x. Epub 2008 Dec 5. No abstract available.

PMID:
19077158
19.

The polymorphism IL-1beta T-31C is associated with a longer overall survival in patients with multiple myeloma undergoing auto-SCT.

Vangsted AJ, Klausen TW, Ruminski W, Gimsing P, Andersen NF, Gang AO, Abildgaard N, Knudsen LM, Nielsen JL, Gregersen H, Vogel U.

Bone Marrow Transplant. 2009 Apr;43(7):539-45. doi: 10.1038/bmt.2008.351. Epub 2008 Nov 10.

PMID:
18997828
20.

A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia.

Gimsing P, Hansen M, Knudsen LM, Knoblauch P, Christensen IJ, Ooi CE, Buhl-Jensen P.

Eur J Haematol. 2008 Sep;81(3):170-6. doi: 10.1111/j.1600-0609.2008.01102.x. Epub 2008 May 27.

PMID:
18510700
21.

Frequent hypermethylation of DBC1 in malignant lymphoproliferative neoplasms.

Grønbaek K, Ralfkiaer U, Dahl C, Hother C, Burns JS, Kassem M, Worm J, Ralfkiaer EM, Knudsen LM, Hokland P, Guldberg P.

Mod Pathol. 2008 May;21(5):632-8. doi: 10.1038/modpathol.2008.27. Epub 2008 Feb 8.

22.

High serum YKL-40 concentration is associated with severe bone disease in newly diagnosed multiple myeloma patients.

Mylin AK, Abildgaard N, Johansen JS, Andersen NF, Heickendorff L, Standal T, Gimsing P, Knudsen LM.

Eur J Haematol. 2008 Apr;80(4):310-7. doi: 10.1111/j.1600-0609.2007.01027.x. Epub 2007 Dec 21.

PMID:
18182077
23.

Myeloma cell expression of 10 candidate genes for osteolytic bone disease. Only overexpression of DKK1 correlates with clinical bone involvement at diagnosis.

Haaber J, Abildgaard N, Knudsen LM, Dahl IM, Lodahl M, Thomassen M, Kerndrup GB, Rasmussen T.

Br J Haematol. 2008 Jan;140(1):25-35. Epub 2007 Nov 12.

PMID:
18005268
24.

Dysregulation of CD47 and the ligands thrombospondin 1 and 2 in multiple myeloma.

Rendtlew Danielsen JM, Knudsen LM, Dahl IM, Lodahl M, Rasmussen T.

Br J Haematol. 2007 Sep;138(6):756-60.

PMID:
17760807
25.

Magnetic resonance investigation of bone marrow following priming and stem cell mobilization.

Chabanova E, Johnsen HE, Knudsen LM, Larsen L, Løgager V, Yingru S, Thomsen HS.

J Magn Reson Imaging. 2006 Dec;24(6):1364-70.

PMID:
17083110
26.

Intensive therapy for multiple myeloma in patients younger than 60 years. Long-term results focusing on the effect of the degree of response on survival and relapse pattern after transplantation.

Lenhoff S, Hjorth M, Turesson I, Westin J, Gimsing P, Wislöff F, Ahlberg L, Carlson K, Christiansen I, Dahl IM, Forsberg K, Brinch L, Hammerström J, Johnsen HE, Knudsen LM, Linder O, Mellqvist UH, Nesthus I, Nielsen JL; Nordic Myeloma Study Group.

Haematologica. 2006 Sep;91(9):1228-33.

27.

Serum YKL-40 concentrations in newly diagnosed multiple myeloma patients and YKL-40 expression in malignant plasma cells.

Mylin AK, Rasmussen T, Johansen JS, Knudsen LM, Nørgaard PH, Lenhoff S, Dahl IM, Johnsen HE; Nordic Myeloma Study Group.

Eur J Haematol. 2006 Nov;77(5):416-24. Epub 2006 Aug 23.

PMID:
16930142
28.

Quality assessment of autografting by probability evaluation: model estimation by clinical end-points in newly diagnosed multiple myeloma patients.

Roer O, Hammerstrøm J, Lenhoff S, Mylin AK, Knudsen LM, Rasmussen T, Johnsen HE; Nordic Myeloma Study Group.

Cytotherapy. 2006;8(1):79-88.

PMID:
16637135
29.

Autologous stem cell transplantation in multiple myeloma: outcome in patients with renal failure.

Knudsen LM, Nielsen B, Gimsing P, Geisler C.

Eur J Haematol. 2005 Jul;75(1):27-33.

PMID:
15946307
30.
31.

Molecular and clinical follow-up after treatment of multiple myeloma.

Rasmussen T, Knudsen LM, Huynh TK, Johnsen HE.

Acta Haematol. 2004;112(1-2):105-10. Review.

PMID:
15179010
32.

[Treatment of cancer with high-dose chemotherapy and autologous stem cell transplantation].

Geisler CH, Daugaard KG, Dickmeiss E, Ifversen M, Knudsen LM.

Ugeskr Laeger. 2003 Dec 8;165(50):4846-9. Danish. No abstract available.

PMID:
14716902
33.

C-MAF oncogene dysregulation in multiple myeloma: frequency and biological relevance.

Rasmussen T, Knudsen LM, Dahl IM, Johnsen HE.

Leuk Lymphoma. 2003 Oct;44(10):1761-6.

PMID:
14692531
34.

FGFR3 dysregulation and clinical outcome in myeloma.

Rasmussen T, Hudlebusch HR, Knudsen LM, Johnsen HE.

Br J Haematol. 2003 Jan;120(1):166. No abstract available.

PMID:
12492593
35.

FGFR3 dysregulation in multiple myeloma: frequency and prognostic relevance.

Rasmussen T, Hudlebusch HR, Knudsen LM, Johnsen HE.

Br J Haematol. 2002 Jun;117(3):626-8.

PMID:
12028033
36.

Frequency and prognostic relevance of cyclin D1 dysregulation in multiple myeloma.

Rasmussen T, Knudsen LM, Johnsen HE.

Eur J Haematol. 2001 Nov-Dec;67(5-6):296-301.

PMID:
11872077
37.

Mobilisation of tumour cells along with CD34+ cells to peripheral blood in multiple myeloma.

Knudsen LM, Rasmussen T, Nikolaisen K, Johnsen HE.

Eur J Haematol. 2001 Nov-Dec;67(5-6):289-95.

PMID:
11872076
38.

Health-related quality of life in multiple myeloma patients receiving high-dose chemotherapy with autologous blood stem-cell support.

Gulbrandsen N, Wisløff F, Brinch L, Carlson K, Dahl IM, Gimsing P, Hippe E, Hjorth M, Knudsen LM, Lamvik J, Lenhoff S, Løfvenberg E, Nesthus I, Nielsen JL, Turesson I, Westin J; Nordic Myeloma Study Group.

Med Oncol. 2001;18(1):65-77.

PMID:
11778972
39.

Kinetic studies during peripheral blood stem cell collection show CD34+ cell recruitment intra-apheresis.

Knudsen LM, Nikolaisen K, Gaarsdal E, Johnsen HE.

J Clin Apher. 2001;16(3):114-9.

PMID:
11746536
40.

[Posttraumatic hyphema induced by tossed frozen caramel candy].

Hansen JA, Knudsen LM.

Ugeskr Laeger. 2001 Aug 6;163(32):4206-7. Danish.

PMID:
11510241
41.

Renal failure in multiple myeloma: reversibility and impact on the prognosis. Nordic Myeloma Study Group.

Knudsen LM, Hjorth M, Hippe E.

Eur J Haematol. 2000 Sep;65(3):175-81.

PMID:
11007053
42.

Selective loss of progenitor subsets following clinical CD34+ cell enrichment by magnetic field, magnetic beads or chromatography separation.

Johnsen HE, Hutchings M, Taaning E, Rasmussen T, Knudsen LM, Hansen SW, Andersen H, Gaarsdal E, Jensen L, Nikolajsen K, Kjaesgârd E, Hansen NE.

Bone Marrow Transplant. 1999 Dec;24(12):1329-36.

43.

Reduced bone marrow stem cell pool and progenitor mobilisation in multiple myeloma after melphalan treatment.

Knudsen LM, Rasmussen T, Jensen L, Johnsen HE.

Med Oncol. 1999 Dec;16(4):245-54.

PMID:
10618687
44.

High numbers of clonal CD19+ cells in the peripheral blood of a patient with multiple myeloma.

Rasmussen T, Kastrup J, Knudsen LM, Johnsen HE.

Br J Haematol. 1999 Apr;105(1):265-7.

PMID:
10233390
45.

Comparison of rhG--CSF primed bone marrow and blood stem cell autografts: an analysis of engraftment in malignant lymphomas and solid tumours.

Knudsen LM, Hansen SW, Daugård G, Jarlbaek L, Agerbaek M, Jensen L, Skovsgård T, Hansen F, Johnsen HE.

Eur J Haematol. 1998 Oct;61(4):229-34.

PMID:
9820628
46.
47.

Flow cytometry comparison of CD34+ subsets in bone marrow and peripheral blood after priming with glycosylated or non-glycosylated rhG-CSF.

Schiødt I, Knudsen LM, Jensen L, Nikolajsen K, Gaarsdal E, Johnsen HE.

Bone Marrow Transplant. 1998 Jun;21(11):1167-9. No abstract available.

48.

["Moon-cars" are dangerous].

Herold N, Knudsen LM, Røck ND.

Ugeskr Laeger. 1998 Apr 27;160(18):2703-5. Danish.

PMID:
9599554
49.

Evaluation of mobilized CD34+ cell counts to guide timing and yield of large-scale collection by leukapheresis.

Knudsen LM, Gaarsdal E, Jensen L, Nikolaisen K, Johnsen HE.

J Hematother. 1998 Feb;7(1):45-52.

PMID:
9507380
50.

[The human hematopoietic stem cell biology and clinical use].

Hansen NE, Hutchings M, Johnsen HE, Knudsen LM, Rasmussen T.

Ugeskr Laeger. 1997 Jun 30;159(27):4253-6. Danish. No abstract available.

PMID:
9229880

Supplemental Content

Loading ...
Support Center